EC
IMNM icon

EntryPoint Capital’s Immunome IMNM Stock Holding History

EntryPoint Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,120
Closed -$243K – 961
2024
Q2 		$243K Buy
20,120
+14,629
+266% +$229K 0.11% 298
2024
Q1 		$136K Buy
5,491
+5,466
+21,864% +$111K 0.12% 267
2023
Q4 		$268 Buy
+25
New +$208 ﹤0.01% 1299

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

EntryPoint Capital's IMNM Position: Q3 2024 in Review

EntryPoint Capital sold out of Immunome (IMNM) in Q3 2024, closing a stake of 20,120 shares — an estimated $243K sold.

EntryPoint Capital first reported a position in IMNM in Q4 2023 and held it in 3 quarters. The position peaked at $243K in Q2 2024. 115 funds tracked by Wall St. Rank hold IMNM as of Q3 2024.

  • EntryPoint Capital reported no remaining Immunome position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 20,120 Immunome shares in Q3 2024, an estimated $243K.
  • EntryPoint Capital first reported a position in Immunome in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Immunome position peaked at $243K in Q2 2024.
  • 115 funds tracked by Wall St. Rank held Immunome as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.